Effects of a probiotic treatment (Enterococcus faecalis) and open-label placebo on symptoms of allergic rhinitis: study protocol for a randomised controlled trial

Abstract

IntroductionSeveral studies suggest that gut microbiota may play an important role in allergic diseases. The present trial aims to examine effects of the probiotic Enterococcus faecalis on symptoms of allergic rhinitis in patients. Effects of this probiotic on the immune system have been reported by several studies, but the majority of the previous trials were animal studies. In addition, it is well known that symptoms in allergic rhinitis are prone to exhibit high placebo responses. Moreover, recent studies report that even placebos without deception (open-label placebos) are highly effective in reducing symptoms of allergic rhinitis. Our study design combines both new approaches to assess effects on allergic symptoms in patients. The objective of this study is to compare the effects of a probiotic treatment (E. faecalis) with effects seen by open-label placebo, concealed placebo treatment and no treatment control.Methods and analysisA total of 120 patients with allergic rhinitis will be randomly assigned to one of four different groups: a double-blind probiotic/placebo group (groups 1 and 2), an open-label placebo group (group 3) and a no-treatment group (group 4) to control for spontaneous variation of symptoms. The primary outcome is the evaluation of allergic symptoms using the Combined Symptoms Medication Score. Furthermore, health-related quality of life is examined (Rhinitis Quality of Life Questionnaire). Secondary outcomes include a visual analogue scale on allergic burden and a second quality of life questionnaire. This report describes the study design of the randomised controlled trial.Ethics and disseminationThe study design was approved by the ethical committee of the UKT Department of Psychosomatic Medicine and Psychotherapy, Tübingen, Germany. The trial is registered at the German Clinical Trials Register (www.drks.de, DRKS00015804). The trial results will be published in peer-reviewed journals and at conferences.Trial registration numberGerman Clinical Trials Register (www.drks.de, DRKS00015804); Pre-results.

Placebo Responses and Placebo Effects in Functional Gastrointestinal Disorders

“…Finally, open label placebo treatment ( 84 ) can be added to a conventional placebo-controlled trial, either with full double-blinded randomization ( 85 ) or allowing patient preferences for either arm, what has been called preference design ( 19 ).…”

Microbiome profiling of nasal extracellular vesicles in patients with allergic rhinitis

“… 4 , 5 Previous studies have confirmed that the microbiome directly affects inflammatory responses in allergic diseases such as AR and asthma. 6 , 7 , 8 Therefore, the study of the composition of the microbiota is of great importance for understanding the pathogenesis of AR.…”

Effects of open-label placebos on test performance and psychological well-being in healthy medical students: a randomized controlled trial

“…To circumvent these challenges, open-label placebo (OLP) interventions administer placebos in an unconcealed fashion with the individual’s awareness and consent. Encouraging pioneering studies suggest beneficial effects of OLP in different clinical conditions, e. g., cancer-related fatigue 16 , chronic back pain 17 , 18 , allergic rhinitis 19 , attention deficit hyperactivity disorder 20 or irritable bowel syndrome 21 . A first meta-analysis of these initial studies confirms these effects 22 .…”